BioXcel Therapeutics, Inc.
NASDAQ:BTAI
0.68 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.38 | 0.375 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.578 | 0.02 | 0.297 | 0.188 | 0.156 | 0.017 | 0.001 | 0 | 0 |
| Gross Profit
| -0.198 | 0.355 | -0.297 | -0.188 | -0.156 | -0.017 | -0.001 | 0 | 0 |
| Gross Profit Ratio
| -0.143 | 0.947 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 82.933 | 91.239 | 52.708 | 57.995 | 25.797 | 14.558 | 2.69 | 1.399 | 0.233 |
| General & Administrative Expenses
| 70.928 | 68.761 | 54.227 | 24.302 | 7.804 | 5.404 | 1.847 | 0.721 | 0 |
| Selling & Marketing Expenses
| 12.485 | 13.006 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 83.202 | 68.761 | 54.227 | 24.302 | 7.804 | 5.404 | 1.847 | 0.721 | 0.403 |
| Other Expenses
| 0.394 | -0.427 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 166.135 | 160 | 106.935 | 82.297 | 33.601 | 19.962 | 4.537 | 2.12 | 0.636 |
| Operating Income
| -166.333 | -159.645 | -106.935 | -82.297 | -33.601 | -19.962 | -4.537 | -2.12 | -0.636 |
| Operating Income Ratio
| -120.531 | -425.72 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -12.72 | -6.112 | 0.004 | 0.128 | 0.633 | 0.692 | -0.002 | 0 | 0 |
| Income Before Tax
| -179.053 | -165.757 | -106.931 | -82.169 | -32.968 | -19.27 | -4.539 | -2.12 | -0.636 |
| Income Before Tax Ratio
| -129.749 | -442.019 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.15 | 6.092 | -0.301 | -0.161 | -0.633 | 0.692 | 0 | -2.12 | 0 |
| Net Income
| -179.053 | -171.849 | -106.63 | -82.008 | -32.335 | -19.27 | -4.539 | -2.12 | -0.636 |
| Net Income Ratio
| -129.749 | -458.264 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -6.15 | -6.13 | -4.04 | -3.78 | -1.99 | -1.32 | -0.3 | -0.14 | -0.04 |
| EPS Diluted
| -6.15 | -6.13 | -4.04 | -3.78 | -1.99 | -1.32 | -0.3 | -0.14 | -0.04 |
| EBITDA
| -166.015 | -157.544 | -106.935 | -82.297 | -34.078 | -20.637 | -4.536 | -2.12 | -0.636 |
| EBITDA Ratio
| -120.301 | -420.117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |